The nation of Zimbabwe has turned down a significant US healthcare agreement valued at $367m (£272m) spanning five years due to the United States' request for sensitive biological samples.
This move was revealed following a official document from December was leaked, which showed President Emmerson Mnangagwa believed the arrangement was "lopsided".
An official representative has since stated that the United States was seeking genetic material for scientific study and commercial gain but was unwilling to share the resulting advantages from any future medical innovations.
"We must now begin the challenging and unfortunate task of ending our health aid in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy indicated the United States had provided over $1.9bn as health assistance to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has called for continued dialogue to reach a agreement acceptable to all parties so the country's critical HIV programme can be sustained.
Wider Implications
Zimbabwe's decision follows a comparable situation in neighbouring Kenya, where a high court halted a similar deal with the US following legal challenges were filed about the safety of citizens' health data.
After resuming the presidency last year, US President Donald Trump has drastically cut overseas assistance and closed the key foreign aid agency.
The agency had administered assistance for the US government, but Trump stated its expenditure was "wasteful" and his administration was pursuing government-to-government deals to boost transparency and responsibility.
As per reports, 16 nations in Africa have to date signed similar agreements, constituting more than $18.3bn in new funding.
Specifics of the Rejected Agreement
The funds for Zimbabwe was intended to gone towards "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this partnership might have yielded extraordinary benefits for Zimbabwean communities, particularly the 1.2 million men, women and children presently receiving HIV treatment through US-supported initiatives," the Ambassador commented.
However, government spokesperson Nick Mangwana said the proposed deal was "asymmetrical".
"Zimbabwe was being asked to surrender its genetic material and health information for a long time, with no equivalent assurance of access to any medical innovations – like vaccines, diagnostics, or treatments – that could be developed from that shared data," he stated.
"In essence, our country would supply the raw materials for medical research with no certainty that the resulting innovations would be available to our population should a future disease outbreak emerge."
Sovereignty and International Frameworks
He also pointed out that the American exit from the global health body and its push of bilateral deals were upending structures previously established via the international organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing framework created to manage potential global health emergencies.
"This system is designed to guarantee that when a country contributes its samples, the benefits – including medicines and cures – are shared equitably, not commercialised solely by those with the funds to create them."
Zimbabwe's reservations over the US deal "are not meant as anti-American sentiment," Mangwana stressed.
"We are open to further discussions with our American counterparts on how future collaboration might be designed in a way that respects the independence and interests of both nations."
Health Experts Response
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it acknowledged the official position, but urged that negotiations must proceed since a large portion of the country's HIV programmes were funded by foreign aid.
"In cases where technical issues arise, including those involving information security or implementation frameworks, these can frequently be resolved through technical clarification and negotiated safeguards," it commented.
The halted deal underscores the ongoing tensions between accepting vital foreign assistance and safeguarding national sovereignty in an ever more data-driven world.